TransMedics Group Inc (TMDX) - Total Assets
Based on the latest financial reports, TransMedics Group Inc (TMDX) holds total assets worth $1.43 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore TMDX cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
TransMedics Group Inc - Total Assets Trend (2006–2025)
This chart illustrates how TransMedics Group Inc's total assets have evolved over time, based on quarterly financial data. See TransMedics Group Inc net assets for net asset value and shareholders' equity analysis.
TransMedics Group Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
TransMedics Group Inc's total assets of $1.43 Billion consist of 59.7% current assets and 40.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.7% |
| Accounts Receivable | $84.28 Million | 7.9% |
| Inventory | $48.88 Million | 4.6% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.95 Million | 0.2% |
| Goodwill | $11.55 Million | 1.1% |
Asset Composition Trend (2006–2025)
This chart illustrates how TransMedics Group Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TMDX market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: TransMedics Group Inc's current assets represent 59.7% of total assets in 2025, a decrease from 85.7% in 2006.
- Cash Position: Cash and equivalents constituted 45.7% of total assets in 2025, down from 60.5% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 7.9% of total assets.
TransMedics Group Inc Competitors by Total Assets
Key competitors of TransMedics Group Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Stratec SE
XETRA:SBS
|
Germany | €443.38 Million |
|
T&R Biofab Co. Ltd
KQ:246710
|
Korea | ₩83.86 Billion |
|
Hironic Co. Ltd
KQ:149980
|
Korea | ₩80.01 Billion |
|
Novacyt
PA:ALNOV
|
France | €40.28 Million |
|
HeraMED Limited
F:1I4
|
Germany | €1.49 Million |
|
Implanet SA
PA:ALIMP
|
France | €18.45 Million |
TransMedics Group Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.74 | 9.10 | 8.96 |
| Quick Ratio | 6.19 | 8.32 | 8.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $527.36 Million | $450.31 Million | $119.97 Million |
TransMedics Group Inc - Advanced Valuation Insights
This section examines the relationship between TransMedics Group Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.82 |
| Latest Market Cap to Assets Ratio | 2.30 |
| Asset Growth Rate (YoY) | 32.9% |
| Total Assets | $1.07 Billion |
| Market Capitalization | $2.46 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values TransMedics Group Inc's assets at a significant premium (2.30x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: TransMedics Group Inc's assets grew by 32.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for TransMedics Group Inc (2006–2025)
The table below shows the annual total assets of TransMedics Group Inc from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.07 Billion | +32.87% |
| 2024-12-31 | $804.08 Million | +13.88% |
| 2023-12-31 | $706.05 Million | +154.76% |
| 2022-12-31 | $277.15 Million | +105.46% |
| 2021-12-31 | $134.89 Million | -11.27% |
| 2020-12-31 | $152.03 Million | +44.38% |
| 2019-12-31 | $105.30 Million | +149.78% |
| 2018-12-31 | $42.16 Million | +13.93% |
| 2017-12-31 | $37.00 Million | -36.32% |
| 2016-12-31 | $58.10 Million | +289.86% |
| 2006-12-31 | $14.90 Million | -- |
About TransMedics Group Inc
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic con… Read more